Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1990014357) HER2 EXTRACELLULAR DOMAIN
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1990/014357 International Application No.: PCT/US1990/002697
Publication Date: 29.11.1990 International Filing Date: 18.05.1990
Chapter 2 Demand Filed: 18.12.1990
IPC:
A61K 39/00 (2006.01) ,C07K 14/71 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
71
for growth factors; for growth regulators
Applicants:
GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard South San Francisco, CA 94080, US
Inventors:
HUDZIAK, Robert, Michael; US
SHEPARD, H., Michael; US
ULLRICH, Axel; DE
Agent:
GREENBLUM, Neil, F.; Sandler, Greenblum & Bernstein 2920 South Glebe Road Arlington, VA 22206, US
Priority Data:
354,31919.05.1989US
Title (EN) HER2 EXTRACELLULAR DOMAIN
(FR) DOMAINE EXTRACELLULAIRE DE HER2
Abstract:
(EN) An extracellular portion of the HER2 molecule, essentially free of transmembrane and cytoplasmic portions, which is antigenic in animals. Isolated DNA encoding the extracellular portion; an expression vector containing the isolated DNA; and a cell containing the expression vector. A process for producing the extracellular domain. A vaccine containing the extracellular domain.
(FR) L'invention concerne une partie extracellulaire de la molécule HER2, essentiellement exempte de la portion transmembranaire et de la portion cytoplasmique, laquelle est un antigénique chez les animaux. L'invention concerne également un ADN isolé codant la portion extracellulaire, un vecteur d'expression contenant l'ADN isolé, et une cellule contenant le vecteur d'expression. L'invention concerne aussi un procédé de production du domaine extracellulaire ainsi qu'un vaccin contenant le domaine extracellulaire.
Designated States: CA
European Patent Office (EPO) (AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)